Conference
Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Pond GR; Armstrong AJ; Wood BA; Brookes M; Leopold LH; Berry WR; De Wit R; Eisenberger MA; Tannock I; Sonpavde G
Volume
29
Pagination
pp. 4582-4582
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2011
DOI
10.1200/jco.2011.29.15_suppl.4582
Conference proceedings
Journal of Clinical Oncology
Issue
15_suppl
ISSN
0732-183X